Citius Pharma CEO to present updates at two major investor conferences in September 2026

Citius Pharmaceuticals CEO Leonard Mazur will present and hold investor meetings at the Moody Capital Solutions and H.C. Wainwright conferences in New York City this September. He will discuss the company's business progress, including the commercialization of LYMPHIR by its subsidiary Citius Oncology and advancements in its late-stage drug pipeline. LYMPHIR, launched in December 2025, targets treatment for certain lymphoma patients, with an initial market estimated over $400 million. The company is also progressing with other therapies like Mino-Lok and Halo-Lido, engaging with the FDA on next steps following successful trials. These presentations aim to update investors on growth and development plans.